About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« What Would You Get Rid Of? | Main | Maybe It Really Is That Hard? »

May 23, 2011

Inadvertent Day Off

Email This Entry

Posted by Derek

Sorry about no new post today - it's been a lively day around here, for a number of reasons (none of them bad). New content tomorrow!

Comments (16) + TrackBacks (0) | Category: Blog Housekeeping


1. oplz on May 23, 2011 1:07 PM writes...

A great day for VRTX! Congrats~

Permalink to Comment

2. canchem on May 23, 2011 1:35 PM writes...

Yeah, fantastic reason to be busy today. Congrats to your higher-ups for their dedication to telaprevir - it was a long road to glory, but now to reap the reweards.

Permalink to Comment

3. Cellbio on May 23, 2011 1:47 PM writes...

Busy...... or didn't plan a blog entry what with the world coming to an end and all and now finding yourself unascended. I can't imagine the disappointment. I am in a bad mood when the coffee and donuts I expect for the morning meeting don't materialize. I'll leave religion to the more hearty.

Permalink to Comment

4. The Ghost of Josh Boger on May 23, 2011 1:51 PM writes...

Are those Pfizer M&A execs I saw leaving the building?

Permalink to Comment

5. drug_hunter on May 23, 2011 2:47 PM writes...

Quelle horreur ! Not a fate I'd wish on my worst enemy...

Permalink to Comment

6. Fishy Fish on May 23, 2011 3:00 PM writes...


I'd imagine lots of free Clam & Chowder at lunch time and some nice cold Samuel Adams just about now (3:59 EDT).

Permalink to Comment

7. toxchick on May 23, 2011 3:05 PM writes...

Congrats to you and to all the other Vertex employees! (and the patients, of course!)Great news!

Permalink to Comment

8. Rick on May 23, 2011 3:11 PM writes...

Great news! I wonder if they're partying at Merck... I suspect not.

Permalink to Comment

9. Hap on May 23, 2011 3:25 PM writes...

Congratulations. Much better to have happy reasons to not post than the many potential unhappy reasons that have been cropping up.

Permalink to Comment

10. petros on May 24, 2011 6:56 AM writes...

Glad to see the FDA didn't queer the pitch having approved boceprivir first.

Hope the heads are OK this morning

And now that book title doesn't seem so absurd even if it took a bit longer to get there

Permalink to Comment

11. anchor on May 24, 2011 6:57 AM writes...

#8, I bet that there was no partying. I mean from what I hear, Merck always took a great pride in the fact that the "drug" was developed with in. But, when it comes to Borceprevir (Merck's me too protease inhibitor for Hep C)it was inherited and second in the running.

Permalink to Comment

12. venividisynthesis on May 24, 2011 7:34 AM writes...

well done

Permalink to Comment

14. MedChem on May 24, 2011 10:47 AM writes...

$800 mil on a new building? What are the managers smoking?! I'm selling my VRTX stock.

Permalink to Comment

15. Hap on May 24, 2011 1:40 PM writes...

Does it include a new retractable roof stadium for the Red Sox? For $800M I'd expect that, at least.

Maybe every chemist gets their own NMR.

Permalink to Comment

16. MedChem on May 24, 2011 3:14 PM writes...

Based on past experience, a new building signals the beginning of the end.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry